Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)

An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Bedford, MA based Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. Lantheus's key Radiopharmaceutical Oncology product is Pylarify, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.

Lantheus Holdings, Inc. (NASDAQ: LNTH) reported that its annual Total Revenue rose from over $1.29 billion in 2023 to over $1.53 billion in 2024, and that is Net Income declined from $326.66 million in 2023 to $312.44 million in 2024.

On May 7, 2025, Lantheus Holdings, Inc. reported its first quarter 2025 results, disclosing that Pylarify sales had decreased year-over-year due to an alleged "temporal competitive disruption." The complaint alleges that defendants further reduced their previous full-year projections due to Pylarify's shortfall, reducing the "year-over-year range to flat-to-low single-digit percent growth for the full year versus our prior view of low-single-digit to mid-single-digit growth."

Then, on August 6, 2025, the Lantheus Holdings, Inc. announced its second quarter 2025 financial results and provideds its business update. Lantheus Holdings, Inc. reported ignificantly reduced growth expectations for Pylarify, which had fallen 8.3% year-over-year, and slashed fiscal year 2025 growth projections further.

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) declined from $111.29 per share in March 2025, to as low as $51.40 per share on August 13, 2025.

The plaintiff claims that between February 26, 2025 and August 5, 2025, the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Pylarify's competitive position; notably, that Lantheus was not equipped to properly assess the pricing and competitive dynamics for Pylarify; the Company failed to properly disclose that its early 2025 price increase, issued despite price erosion the year prior, created an opportunity for competitive pricing to flourish, risking Pylarify's price point, revenue, and overall growth potential.

Those who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.